PsoriasisPhase 2N/ZNCT07489885
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
A Phase 2 study testing D-2570 Tablet in people with Psoriasis, run by InventisBio Co., Ltd at 20 sites in United States.
Trial summary
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Psoriasis
- What is being tested?
- D-2570 Tablet
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 75 participants
- Where
- 20 sitesUnited States
- Study dates
- 3 Jun 2026to Dec 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent
- Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.
- Within normal ranges of laboratory assessments
Who cannot join
- Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator
Trial locations and contacts
20 sites in 1 country. Contact the study team or a site near you to ask about taking part.
20 sites in 1 country
United States20 sites, 20 recruiting
- Recruiting
Study Center
Birmingham, Alabama, 35244
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Recruiting
Study Center
Chula Vista, California, 91910
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Clarksville, Indiana, 40241
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Fort Lauderdale, Florida, 33308
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Fountain Valley, California, 92708
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Fremont, California, 94538
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Idaho Falls, Idaho, 83404
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Los Angeles, California, 90017
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Los Angeles, California, 90024
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Louisville, Kentucky, 40241
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Mayfield Heights, Ohio, 44124
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Miramar, Florida, 33027
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Ocala, Florida, 34470
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Philadelphia, Pennsylvania, 19103
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Phoenix, Arizona, 85008
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Recruiting
Study Center
San Antonio, Texas, 78218
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
San Diego, California, 92123
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Sandy Springs, Georgia, 30328
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Savannah, Georgia, 31419
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
- Not yet recruiting
Study Center
Tampa, Florida, 33607
Kathryn Stazzone, 302-519-5966, kathryn.stazzone@inventisbio.com
About this study
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
Read the detailed description
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants with Moderate to Severe Plaque Psoriasis
- Conditions
- Psoriasis
- Being tested
- D-2570 Tablet, Placebo Tablets
- Keywords
- Moderate to Severe Plaque Psoriasis
- Medical subject headings
- Psoriasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
D-2570 TabletDrug
Active Treatment
Placebo TabletsDrug
Identical Tablet
| Study group | Role | What they receive |
|---|---|---|
| D-2570 low dose | Active comparator | Low dose of D-2570 Receives: Drug: D-2570 Tablet |
| D-2570 High Dose | Active comparator | medium dose level of D-2570 Receives: Drug: D-2570 Tablet |
| Placebo | Placebo comparator | Placebo arm Receives: Drug: Placebo Tablets |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement in PASI-90
Proportion of participants achieving at least a 90% improvement from baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12
Measured: Assessment completed after 12 weeks of treatment/placebo
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2026
- Study start3 Jun 2026
- Primary completionAug 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PsoriasisStudies of the same condition, open and under way.
- More trials run by InventisBio Co., LtdThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 75 participants (estimated)
Sponsor and investigators
- Lead sponsor
- InventisBio Co., Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07489885
- Sponsor's protocol ID
- D2570-207
- Acronym
- N/Z
- Status last verified
- Mar 2026
- First submitted
- 18 Mar 2026
- Last updated
- 9 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis
- ClinicalTrials.gov ID
- NCT07489885
- Acronym / sponsor ID
- N/Z / D2570-207
- Conditions
- Psoriasis
- Keywords
- Moderate to Severe Plaque Psoriasis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- InventisBio Co., LtdIndustry (pharma, biotech, devices)
- Study start
- 3 Jun 2026 (actual)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 24 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
Detailed description
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants with Moderate to Severe Plaque Psoriasis
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| D-2570 low dose | Active comparator | Drug: D-2570 TabletLow dose of D-2570 |
| D-2570 High Dose | Active comparator | Drug: D-2570 Tabletmedium dose level of D-2570 |
| Placebo | Placebo comparator | Drug: Placebo TabletsPlacebo arm |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent
- Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.
- Within normal ranges of laboratory assessments
Key exclusion criteria (1 listed)
- Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| D-2570 TabletActive Treatment | Drug | D-2570 High Dose, D-2570 low dose |
| Placebo TabletsIdentical Tablet | Drug | Placebo |
Primary outcome
Improvement in PASI-90
Time frame: Assessment completed after 12 weeks of treatment/placebo
Proportion of participants achieving at least a 90% improvement from baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Psoriasis
RecruitingPhase 4
A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
Psoriasis, Colitis, Ulcerative
Active, not recruitingPhase 3
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
Plaque Psoriasis
RecruitingObservational study
A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
Psoriasis
Active, not recruitingPhase 3
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Crohn Disease, Colitis, Ulcerative
RecruitingObservational study
A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice
Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing D-2570 Tablet in people with Psoriasis, run by InventisBio Co., Ltd at 20 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kathryn Stazzone (3025195966, kathryn.stazzone@inventisbio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement in PASI-90 (time frame: Assessment completed after 12 weeks of treatment/placebo). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.